Streetbeat News

SCPX

Scorpius Holdings, Inc.

https://www.scorpiusbiologics.com

Industry

Biotechnology

Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Scorpius Holdings, Inc (NYSE American: SCPX) has expanded its biologic manufacturing capabilities, resulting in a threefold revenue increase for the first half of 2024. The company raised $14.4 million to support growth and transition key clients to full-scale manufacturing.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 12:14 pm

Scorpius Holdings reported a Q2 EPS of $(26.98) and revenue of $0.8M, an increase from $0.7M year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 1:28 pm

Scorpius Holdings has announced a new pricing of a $12.5 million underwritten public offering, consisting of 12.5 million shares of common stock or pre-funded warrants. The company also has a 45-day option to purchase an additional 1.875 million shares. Additionally, Scorpius Holdings has received approval for a financial viability exception from the NYSE American.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:51 pm

U.S. stocks traded higher with the Dow Jones, NASDAQ, and S&P 500 all posting gains. Walt Disney Co reported better-than-expected earnings, while shares of Aditxt, G1 Therapeutics, and Richtech Robotics surged. Scorpius Holdings, Expion360, and Talis Biomedical saw significant declines.

Portfolio Pulse from Avi Kapoor

August 07, 2024 | 2:38 pm

Fortinet shares surged 17% in pre-market trading after reporting better-than-expected Q2 results and issuing strong guidance. Other notable pre-market movers include Richtech Robotics, Lumen Technologies, and Upstart Holdings, among others.

Portfolio Pulse from Avi Kapoor

August 07, 2024 | 10:04 am

Scorpius Holdings, Inc. (NYSE:SCPX) has announced surpassing $100 million in near-term business development opportunities across government and commercial sectors. The company expects these opportunities to translate into substantial booked business and associated revenues over the next two quarters. Key opportunities include new commercial customers, repeat client bookings, expanded scope of work with existing clients, and government proposals for new facilities and programs. CEO Jeff Wolf expects many of these opportunities to close before the year's end, significantly boosting revenue and cash flow. Despite this positive outlook, SCPX shares closed lower by 8.09% at $4.72 on Monday.

Portfolio Pulse from Anusuya Lahiri

August 06, 2024 | 12:16 pm

Scorpius Holdings, Inc. (NYSE:SCPX) announced that the NYSE Regulation has withdrawn its delisting determination, and the company's common stock will resume trading on the NYSE American on August 2, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:06 pm

Scorpius Holdings' board has approved a 1-for-200 reverse stock split of its common stock, effective July 17, 2024. The stock will trade on a post-split basis on the OTC Markets under the ticker symbol SCPX starting July 18, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 8:33 pm

Ovid Therapeutics shares dropped 65.7% after Takeda's Skyline study in Dravet syndrome missed its primary endpoint. Other notable stock movements include Interactive Strength, Mustang Bio, Allego, and Scinai Immunotherapeutics among gainers, and Aerovate Therapeutics, Kaival Brands Innovations, and Workhorse Group among losers.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 5:21 pm

US stocks showed mixed performance with the Dow Jones falling over 100 points, while the NASDAQ saw a slight rise. Key movers included Mustang Bio, Allego N.V., and Scinai Immunotherapeutics, which saw significant gains, while Aerovate Therapeutics, Scorpius Holdings, and Ovid Therapeutics experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 1:40 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.